Search Results - Peter Mol
- Showing 1 - 4 results of 4
-
1
Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry by Felix Lindberg, Natanael Øigaard, Marco Metra, Giuseppe M. C. Rosano, Ulf Dahlström, Peter Mol, Camilla Hage, Lars H. Lund, Gianluigi Savarese
Published in PLoS ONE (2024-01-01)Get full text
Article -
2
Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis by Judith M Vonk, Eelko Hak, Katrien Oude Rengerink, Hubert G M Niesters, Debbie van Baarle, Maarten J Bijlsma, Guiling Zhou, Stefan Verweij, Stijn de Vos, Anna Maria Gerdina Pasmooij, Peter Mol
Published in BMJ Open Respiratory Research (2023-07-01)Get full text
Article -
3
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy by Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Michael Berntgen, Mira Pavlovic, Peter Mol, Jürgen Wasem, Walter Van Dyck, Antonella Cardone, Christian Dierks, Anja Schiel, Renato Bernardini, Oriol Solà-Morales, Jörg Ruof, Wim Goettsch
Published in Health Research Policy and Systems (2024-07-01)Get full text
Article -
4
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators by Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof
Published in Journal of Market Access & Health Policy (2024-03-01)Get full text
Article